BioXplor is developing an AI and network-based drug discovery platform for prioritization of drug combinations for complex diseases for pharma and biotech. The platform prioritises single assets or entire drug pipelines, with a unique safety and efficacy based prioritization model for multiple drug targets and drug combination candidates. In response to the pandemic, BioXplor is positioning the platform for antiviral and anti-inflammatory COVID-19 drug combinations, and is leveraging this to build a pipeline of biotech and academic partners and clients.